Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from PureTech Health ( (GB:PRTC) ) is now available.
PureTech Health has launched Celea Therapeutics, a new entity focused on transforming the treatment of respiratory diseases, with former Teva North America CEO Sven Dethlefs leading the initiative. Celea’s lead program, deupirfenidone (LYT-100), is a Phase 3-ready candidate aimed at treating idiopathic pulmonary fibrosis (IPF), a severe lung disease. The launch underscores PureTech’s commitment to advancing innovative therapies through focused structures, and the appointment of Dr. Dethlefs, with his extensive experience, is expected to drive the program’s success. The development of deupirfenidone, which has shown promising Phase 2b results, represents a significant opportunity in the IPF market, which is currently underserved by existing treatments.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Spark’s Take on GB:PRTC Stock
According to Spark, TipRanks’ AI Analyst, GB:PRTC is a Neutral.
PureTech Health’s overall stock score is driven by its strong earnings call performance and undervalued valuation, despite financial performance challenges. Technical indicators suggest moderate market momentum, while corporate events are already reflected in the earnings call analysis.
To see Spark’s full report on GB:PRTC stock, click here.
More about PureTech Health
PureTech Health is a clinical-stage biotherapeutics company focused on developing new classes of medicine to transform the lives of patients with devastating diseases. The company has a broad portfolio of therapeutics and therapeutic candidates, some of which have been approved by the U.S. Food and Drug Administration. PureTech’s R&D model emphasizes capital-efficient innovation and collaboration with a network of scientists and industry leaders.
Average Trading Volume: 341,806
Technical Sentiment Signal: Strong Sell
Current Market Cap: £312.7M
See more data about PRTC stock on TipRanks’ Stock Analysis page.